ESMO Asia 2025 | How will the KEYNOTE-905 trial be practice changing in bladder cancer?
Christof Vulsteke
• 16 Dec 2025
Christof Vulsteke, MD, PhD, AZ Maria Middelares, Ghent, Belgium, comments on how data from the KEYNOTE-905 study (NCT03924895) may redefine perioperative treatment standards and surgical timing for patients with muscle-invasive bladder cancer (MIBC). The significant reduction in risk of recurrence or progression, and high rate of pathological complete response, supporting the use of enfortumab vedotin and pembrolizumab as a treatment option for cisplatin-ineligible patients. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
